Generic DIMENHYDRINATE INN equivalents, pharmaceutical patent expiry and freedom to operate

Sponsor	Phase
Mount Sinai Hospital, Canada	PHASE2
Preeyaporn Jirakittidul	NA
The University of The West Indies	Early Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	DIMENHYDRINATE	dimenhydrinate	INJECTABLE;INJECTION	084316-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs Teva	DIMENHYDRINATE	dimenhydrinate	INJECTABLE;INJECTION	080615-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Nexgen Pharma Inc	DIMENHYDRINATE	dimenhydrinate	TABLET;ORAL	085985-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 2, 2026

Dimenhydrinate is a mature, genericized over-the-counter motion-sickness medicine with no meaningful remaining product exclusivity. The market is led by the Dramamine brand, private-label products, and pharmacy generics. Revenue growth depends primarily on brand pricing, retail distribution, travel activity, product extensions, and consumer advertising rather than patent protection. No reliable public source reports standalone global dimenhydrinate sales because manufacturers generally combine the product with broader OTC portfolios.

What is dimenhydrinate and how is it used?

Dimenhydrinate is an antihistamine used primarily to prevent and treat motion sickness. It is chemically related to diphenhydramine and is commonly sold in 50 mg tablets, chewable tablets, liquid products, and combination travel-health formats.

In the United States, the standard adult label commonly directs users to take 50 mg to 100 mg every four to six hours, with a maximum daily dose of 400 mg. Pediatric dosing varies by age and product labeling. The drug can cause drowsiness, impaired coordination, dry mouth, blurred vision, and other anticholinergic effects. Alcohol, sedatives, and activities requiring alertness create additional safety concerns.

Dimenhydrinate is sold under several brand and private-label names:

Product or category	Typical positioning	Commercial status
Dramamine Original Formula	Motion-sickness prevention and treatment	Leading U.S. branded product
Store-brand dimenhydrinate	Lower-price equivalent	Broad pharmacy and mass-retail availability
Generic dimenhydrinate	Prescription or OTC-equivalent supply	Multiple manufacturers
Chewable and liquid products	Pediatric and convenience formats	Retail and travel channels
Combination products	Motion sickness or nausea positioning	Smaller niche segments

Dramamine is marketed by Prestige Consumer Healthcare, whose portfolio includes multiple OTC brands. Prestige does not publicly report Dramamine revenue as a standalone line item, so brand-level sales and margins cannot be confirmed from public filings (Prestige Consumer Healthcare, 2024).

How large is the dimenhydrinate market?

The dimenhydrinate market is a mature subsegment of the global OTC antiemetic and motion-sickness market. Public market-research estimates vary substantially because reports use different definitions, geographies, channels, and product groupings. They often combine dimenhydrinate with meclizine, diphenhydramine, scopolamine, ginger products, and other nausea treatments.

A defensible conclusion is that dimenhydrinate is a meaningful but relatively small OTC category compared with broad antihistamine, analgesic, gastrointestinal, and cough-and-cold markets. Standalone revenue is not disclosed by leading manufacturers.

Market structure

The category has five commercial characteristics:

Brand recognition is concentrated in Dramamine.
Generic substitution is easy because the active ingredient and dosage strengths are standardized.
Retail shelf placement and travel-season demand influence sell-through.
Private-label products pressure prices.
Product extensions create more defensible margins than the base tablet.

Demand is seasonal but less volatile than prescription medicines. Sales typically rise during summer travel, holidays, cruise activity, school vacations, and periods of increased air and road travel.

What is the financial trajectory for dimenhydrinate?

Dimenhydrinate has a mature, cash-generative financial profile rather than a high-growth pharmaceutical trajectory. Unit demand is relatively stable, while net sales are shaped by price increases, promotional intensity, product mix, and retail distribution.

Revenue drivers

The principal revenue drivers are:

Travel and leisure activity
Brand advertising
Retail distribution
Online search and e-commerce placement
Private-label penetration
Chewable, liquid, and less-drowsy product extensions
International availability
Consumer concern about sedation

Prestige Consumer Healthcare reports company-wide results rather than standalone Dramamine revenue. Its financial disclosures therefore support analysis of the brand owner’s overall OTC performance, but not a precise dimenhydrinate revenue forecast (Prestige Consumer Healthcare, 2024).

Margin dynamics

The base 50 mg tablet is likely to have lower margins than branded extensions because:

Active-ingredient manufacturing is established.
Several suppliers can produce equivalent products.
Retailers can switch between manufacturers.
Consumers can compare prices easily.
Private-label products limit price expansion.

Branded chewables, liquids, travel kits, and differentiated formulas can generate better gross margins because consumers pay for convenience, taste, packaging, or perceived brand reliability. These products also carry greater formulation, packaging, and marketing costs.

Scenario outlook

Scenario	Market effect	Financial implication
Base case	Stable travel demand and moderate retail pricing	Low-single-digit nominal growth or flat real growth
Upside case	Strong travel recovery, effective brand marketing, higher mix of extensions	Higher branded sales and improved product mix
Downside case	Private-label substitution, weaker travel, retailer price pressure	Unit stability with declining branded revenue
Cost-inflation case	Higher packaging, logistics, or API costs	Margin compression unless prices rise
Regulatory or safety case	Greater concern about sedation or anticholinergic effects	Potential shift toward meclizine or non-drug alternatives

The long-term risk is not patent expiry. That event occurred decades ago. The commercial risk is erosion of branded share by private-label dimenhydrinate, meclizine, non-drug products, and retailer-owned travel-health brands.

When does dimenhydrinate lose exclusivity?

Dimenhydrinate has no meaningful current exclusivity period in the United States.

The compound has been marketed for many decades, and the active ingredient is available through generic and private-label channels. Any original composition, formulation, or manufacturing patents would have expired long ago. The product therefore does not have a patent cliff comparable to a modern prescription medicine.

Exclusivity category	Current position
New chemical entity exclusivity	None
Orphan-drug exclusivity	None identified
Pediatric exclusivity	None identified
Current U.S. composition patent	No commercially material patent identified
Current branded formulation moat	Limited and product-specific
OTC monograph status	Primary regulatory framework
Generic substitution risk	High

There is no single “dimethydrinate patent expiration date” that determines market entry. The relevant commercial question is whether a particular branded presentation has enforceable formulation, packaging, trademark, or device rights.

What patents protect dimenhydrinate products?

The core dimenhydrinate molecule is not protected by a commercially relevant active patent estate. Modern patent risk may exist around a specific product presentation, but that risk normally concerns a formulation, delivery system, packaging configuration, flavor system, or combination product rather than the active ingredient itself.

Formulation patents

Potential formulation claims could cover:

Chewable tablets
Liquid suspensions
Extended-release products
Taste-masking systems
Fast-dissolving dosage forms
Combination products
Unit-dose travel packaging
Coated tablets
Pediatric delivery formats

These rights would need to be assessed at the individual product level. They do not prevent competitors from selling standard immediate-release dimenhydrinate tablets.

Method-of-use patents

Method-of-use patent protection is weak for the traditional motion-sickness indication because the use is long established. A later patent could theoretically claim a specific dosing regimen, patient population, combination, or delivery method, but such rights would not normally block conventional OTC dimenhydrinate sales.

Trademark protection

Trademark rights are more commercially important than patents. Dramamine brand recognition, packaging, trade dress, and advertising support pricing power. Trademark rights do not prevent generic manufacturers from selling dimenhydrinate under the established generic name.

What is the FDA regulatory status of dimenhydrinate?

Dimenhydrinate is regulated primarily as an OTC drug. FDA’s OTC monograph framework identifies acceptable conditions for nonprescription use, including active ingredient, indication, dosage, labeling, and warnings (U.S. Food and Drug Administration, 2023).

The relevant federal OTC framework for antihistamine products includes 21 C.F.R. Part 336, which addresses certain internal analgesic, antipyretic, and antirheumatic products and related OTC conditions. Product-specific regulatory treatment depends on the dosage form, labeling, active ingredients, and applicable monograph or approved application.

Manufacturers must comply with:

Current good manufacturing practice requirements
Drug Facts labeling
Adverse-event reporting
Product quality and stability requirements
Child-resistant packaging rules where applicable
FDA registration and listing requirements
Applicable OTC monograph or approved application requirements

FDA’s OTC Drug Facts system and product listings provide the most relevant regulatory reference points for marketed products (U.S. Food and Drug Administration, n.d.-a; U.S. Food and Drug Administration, n.d.-b).

What is the Orange Book status of dimenhydrinate?

The Orange Book is principally designed to list approved prescription drug products and their therapeutic-equivalence information. Standard OTC dimenhydrinate products are generally not managed as a conventional Orange Book patent-listing strategy.

As a result:

Orange Book patent listings are not the main barrier to dimenhydrinate entry.
Paragraph IV certifications are not the normal competitive mechanism for ordinary OTC monograph products.
Generic manufacturers typically compete through OTC compliance, manufacturing capacity, retail distribution, and price.
A prescription product with a specific approved application could have different Orange Book treatment, but that would be product-specific.

A search for “dimenhydrinate Orange Book patents” should not be treated as equivalent to a prescription-drug patent landscape. The principal commercial rights are trademarks, retailer relationships, formulation know-how, and manufacturing economics.

Which companies are challenging dimenhydrinate exclusivity?

No major current Paragraph IV campaign is central to the dimenhydrinate market. The product is already subject to broad generic and private-label competition.

Competition comes from:

Generic drug manufacturers
Retail pharmacy private-label suppliers
OTC brand owners
International manufacturers
Contract manufacturers
Alternative motion-sickness products

The most direct competitors are products containing meclizine, diphenhydramine, scopolamine, or non-drug ingredients such as ginger. Dramamine also competes internally across different formulas, including products positioned around reduced drowsiness or longer duration.

What patent litigation affects dimenhydrinate?

No major, publicly prominent patent litigation currently defines the U.S. dimenhydrinate market. The absence of litigation is consistent with the product’s age, generic availability, and limited patent value.

Potential disputes would more likely involve:

Trademark infringement
False or misleading advertising
Packaging and trade dress
Product liability
Manufacturing quality
Retail distribution agreements
OTC labeling compliance

Patent litigation could arise around a new formulation or combination product, but it would not normally affect the established immediate-release dimenhydrinate market.

What generic launch risks exist for dimenhydrinate?

Generic launch risk is high for any branded standard tablet because technical barriers are low. A competitor generally needs:

A compliant source of dimenhydrinate
Acceptable manufacturing controls
Stable product specifications
FDA-compliant labeling
Retail or wholesale distribution
Adequate quality documentation
Packaging that meets applicable requirements

The principal barriers are commercial rather than scientific. Retailers may demand low prices, large-volume supply, and consistent service levels. Product recalls or supply interruptions can create temporary advantages for competitors with available inventory.

Manufacturing and intellectual-property barriers

Dimenhydrinate manufacturing is not generally protected by a difficult-to-replicate platform. The active ingredient is established, and standard solid-dose production is widely understood. Barriers may still arise from:

API supplier qualification
Impurity control
Batch consistency
Taste masking
Liquid-product stability
Packaging-line capacity
International quality audits
Retailer vendor approval

These barriers can slow entry but do not create durable exclusivity comparable to a complex biologic or sterile injectable.

How does dimenhydrinate compare with competing motion-sickness drugs?

Product	Main advantage	Main disadvantage	Competitive position
Dimenhydrinate	Broad availability and strong Dramamine recognition	Sedation and frequent dosing	Core mass-market product
Meclizine	Longer dosing interval and often perceived as less sedating	May be less suitable for some consumers	Major oral competitor
Diphenhydramine	Familiar antihistamine and broad availability	Sedation and anticholinergic effects	Substitute product
Scopolamine patch	Extended duration and prescription delivery	Prescription access, cost, adverse effects	Higher-value niche
Ginger and non-drug products	Perceived natural or lower-sedation option	Variable consumer response	Growing alternative segment

Meclizine creates the strongest direct substitution pressure because consumers may prioritize longer duration or lower perceived sedation. Scopolamine is less directly substitutable because it is a prescription transdermal product with a different access and pricing model.

What licensing deals affect dimenhydrinate?

No major public licensing transaction currently appears to determine the dimenhydrinate market. The principal branded asset, Dramamine, is managed within Prestige Consumer Healthcare’s OTC portfolio.

Licensing value is limited because:

The active ingredient is generic.
Manufacturing technology is widely available.
Product switching costs are low.
The market does not depend on a single patented platform.
Retail distribution is more important than molecular rights.

Transactions involving dimenhydrinate are more likely to concern brand ownership, contract manufacturing, regional distribution, or portfolio acquisitions than exclusive molecule licenses.

What geographic markets are important for dimenhydrinate?

Dimenhydrinate is sold in multiple countries, but regulatory treatment and brand strength vary. The United States is commercially important because of Dramamine’s recognition and the scale of its OTC retail market. Canada, Europe, Latin America, and parts of Asia have additional motion-sickness products and may show different preferences for dimenhydrinate, meclizine, or other antihistamines.

Geographic performance depends on:

OTC versus prescription classification
Local travel patterns
National labeling rules
Pharmacy distribution
Brand recognition
Price controls
Local manufacturing
Import requirements

Patent coverage is unlikely to be the main geographic differentiator. Regulatory compliance and distribution access are more important.

How strong is the dimenhydrinate patent estate?

The patent estate is weak for the core product and potentially moderate for selected newer presentations.

Asset type	Patent strength	Commercial relevance
Core dimenhydrinate molecule	Very low	No meaningful current exclusivity
Standard 50 mg tablet	Very low	High generic exposure
Chewable or liquid formulation	Low to moderate	Product-specific differentiation
Combination product	Low to moderate	Depends on claim scope and approval pathway
Delivery system	Moderate in narrow cases	Can support premium positioning
Trademark and trade dress	Moderate	Important for branded shelf presence
Manufacturing know-how	Low to moderate	May affect quality and supply reliability

The defensible value of a dimenhydrinate brand comes from consumer awareness, retail execution, product design, and marketing. Patent rights are secondary.

What is the outlook for generic and branded launches?

A new conventional dimenhydrinate tablet would face intense price competition and limited differentiation. A stronger launch opportunity would involve:

A palatable pediatric format
A lower-sedation positioning supported by compliant labeling
A convenient extended-duration format
A travel kit or combination package
A liquid with improved stability or taste
Strong digital and retail distribution
International markets with weaker incumbent brands

Any launch using novel efficacy or safety claims would face regulatory scrutiny. Product positioning must remain consistent with FDA labeling and applicable OTC requirements.

Key Takeaways

Dimenhydrinate is a mature OTC medicine with no meaningful current molecule-level exclusivity.
Dramamine is the leading U.S. branded franchise, but its standalone revenue is not publicly disclosed.
Generic and private-label competition creates high substitution and pricing pressure.
Patent risk is concentrated in specific formulations, combinations, delivery systems, or packaging rather than the active ingredient.
Paragraph IV litigation and Orange Book disputes are not central to ordinary OTC dimenhydrinate competition.
Financial performance depends on travel demand, brand marketing, retail distribution, product mix, and price realization.
Meclizine is the principal oral substitute, while scopolamine competes in a prescription niche.
Manufacturing and regulatory compliance matter more than patent barriers for new entrants.
The most attractive growth opportunities are differentiated dosage forms, convenience products, and geographic expansion.

FAQs

Is dimenhydrinate still under patent?

No commercially meaningful patent protection for the core dimenhydrinate molecule is generally expected to remain. Individual products may have narrower formulation, packaging, or delivery-system rights.

Is Dramamine the same as dimenhydrinate?

Dramamine Original Formula contains dimenhydrinate. The Dramamine brand also includes products based on other active ingredients and differentiated formulations, so the active ingredient must be checked for each product.

Can a company launch a generic dimenhydrinate product without a Paragraph IV challenge?

For a conventional OTC product marketed under applicable monograph conditions, competition generally does not depend on a Paragraph IV certification. The regulatory pathway differs from that used for many prescription products with Orange Book-listed patents.

Which drug competes most directly with dimenhydrinate?

Meclizine is the closest oral competitor because it is also used for motion sickness and is often selected for its longer dosing interval. Diphenhydramine and scopolamine are other important alternatives.

Is dimenhydrinate a high-growth pharmaceutical market?

No. It is a mature, low-growth OTC category. Growth is more likely to come from pricing, branded product extensions, e-commerce, and travel recovery than from increased penetration of the core molecule.

References

Prestige Consumer Healthcare, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
U.S. Food and Drug Administration. (2023). Over-the-counter monograph drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.-b). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 336: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-336

US Patents:	0
Tradenames:	1
Applicants:	8
NDAs:	9
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	23
Patent Applications:	5,826
Drug Prices:	Drug price trends for DIMENHYDRINATE
What excipients (inactive ingredients) are in DIMENHYDRINATE?	DIMENHYDRINATE excipients list
DailyMed Link:	DIMENHYDRINATE at DailyMed

DIMENHYDRINATE - Generic Drug Details

What are the generic sources for dimenhydrinate and what is the scope of patent protection?

Summary for DIMENHYDRINATE

Recent Clinical Trials for DIMENHYDRINATE

Medical Subject Heading (MeSH) Categories for DIMENHYDRINATE

Anatomical Therapeutic Chemical (ATC) Classes for DIMENHYDRINATE

US Patents and Regulatory Information for DIMENHYDRINATE

Dimenhydrinate Market Dynamics, Financial Trajectory, Patents, and Competitive Landscape